Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Launched by HUNAN PROVINCE TUMOR HOSPITAL · Mar 24, 2020

Keywords

ClinConnect Summary

This clinical trial is studying different treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) who have specific genetic changes, known as oncogenic mutations, including mutations in the EGFR, ALK, ROS1, and MET genes. The goal is to understand how these treatments can improve survival outcomes for patients with this type of cancer.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of Stage IV non-small cell lung cancer with one of the mentioned gene mutations. They should also be in reasonably good health, with a predicted survival of at least 12 weeks. Participants can expect to receive treatment tailored to their specific genetic mutation and will be closely monitored throughout the study. The trial is currently recruiting participants of all genders, and understanding what the trial involves is essential, as patients will need to provide informed consent before joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
• • 2. Age ≥ 18 years.
• • 3. Histologically or cytologically confirmed, Stage IV NSCLC.
• • 4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
• • 5. ECOG 0-1.
• • 6. Predicted survival ≥ 12 weeks.
• • 7. Adequate bone marrow hematopoiesis and organ function
• • 8. Presence of measurable lesions according to RECIST 1.1.
• Exclusion Criteria:
• • The patient did not match from the Inclusion Criteria.